Tuesday, January 29, 2019 12:50:04 PM
How about another one....
Feb 18-21 San Francisco
Alzheimer Society International Congress (ASIC 2019)
ASIC 2019 is a leading forum in Alzheimer research and dementia care. The Congress will highlight the latest accomplishments in Alzheimer research and best practice in patient care.
The theme of the 2019 Congress is “International United Front Against Alzheimer's”.
ASIC 2019 encourages new concepts and hypotheses on the etiology and potential prevention or treatment therapy, and best practice in Alzheimer’s and Dementia care. New ideas and alternatives to Amyloid cascade hypothesis such as Tau hypothesis, Calcium hypothesis, Inflammation hypothesis, Cholinergic and Oxidative stress hypothesis, Glucose hypometabolism, Endocrine pathway, Bacteria-derived metabolites and other new ideas with supporting data are welcome at the ASIC.
NEW FEATURES OF THE ASIC 2019:
<> Presenting latest findings in Alzheimer research and best practices in dementia patient care.
<> Featuring alternative approaches to the amyloid hypothesis.
<> Launching the UNITED FRONT AGAINST ALZHEIMER'S, to fund innovative approaches and clinical trials in Alzheimer's.
<> Formulating a new strategy to find a prevention or a cure of Alzheimer's by 2025.
<> Introducing the GLOBAL VIRTUAL ALZHEIMER COMMUNITY to collaborate in research and practices in dementia patient care.
MEETING VENUE
The ASIC 2019 will be held at the San Francisco Airport CROWNE PLAZA:
1177 Airport Boulevard, Burlingame, CA 94010
The hotel is conveniently located within 1.5 miles from the San Francisco International Airport, and 15 miles from downtown San Francisco. For more information about hotel and reservation, please visit Hotel Information.
Dr. Christopher Missling (*)
Anavex Life Sciences Corp.
New York, NY 10019 USA
http://www.alzint.com/presenters.html
Feb 18-21 San Francisco
Alzheimer Society International Congress (ASIC 2019)
ASIC 2019 is a leading forum in Alzheimer research and dementia care. The Congress will highlight the latest accomplishments in Alzheimer research and best practice in patient care.
The theme of the 2019 Congress is “International United Front Against Alzheimer's”.
ASIC 2019 encourages new concepts and hypotheses on the etiology and potential prevention or treatment therapy, and best practice in Alzheimer’s and Dementia care. New ideas and alternatives to Amyloid cascade hypothesis such as Tau hypothesis, Calcium hypothesis, Inflammation hypothesis, Cholinergic and Oxidative stress hypothesis, Glucose hypometabolism, Endocrine pathway, Bacteria-derived metabolites and other new ideas with supporting data are welcome at the ASIC.
NEW FEATURES OF THE ASIC 2019:
<> Presenting latest findings in Alzheimer research and best practices in dementia patient care.
<> Featuring alternative approaches to the amyloid hypothesis.
<> Launching the UNITED FRONT AGAINST ALZHEIMER'S, to fund innovative approaches and clinical trials in Alzheimer's.
<> Formulating a new strategy to find a prevention or a cure of Alzheimer's by 2025.
<> Introducing the GLOBAL VIRTUAL ALZHEIMER COMMUNITY to collaborate in research and practices in dementia patient care.
MEETING VENUE
The ASIC 2019 will be held at the San Francisco Airport CROWNE PLAZA:
1177 Airport Boulevard, Burlingame, CA 94010
The hotel is conveniently located within 1.5 miles from the San Francisco International Airport, and 15 miles from downtown San Francisco. For more information about hotel and reservation, please visit Hotel Information.
Dr. Christopher Missling (*)
Anavex Life Sciences Corp.
New York, NY 10019 USA
http://www.alzint.com/presenters.html
Recent AVXL News
- Form 8-K - Current report • Edgar (US Regulatory) • 05/22/2026 12:15:26 PM
- Anavex Life Sciences Receives Expected Nasdaq Delinquency Notification • GlobeNewswire Inc. • 05/22/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/15/2026 08:15:25 PM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/14/2026 08:15:30 PM
- Form NT 10-Q - Notification of inability to timely file Form 10-Q or 10-QSB • Edgar (US Regulatory) • 05/11/2026 08:30:22 PM
- CEO Transition and Delayed SEC Filing Put Anavex (AVXL) Leadership Changes in Focus • IH Market News • 05/06/2026 02:52:36 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/06/2026 11:04:59 AM
- Anavex Life Sciences Board of Directors Appoints Former Senior Vice President of Clinical Development Terrie Kellmeyer, PhD, as Interim Chief Executive Officer • GlobeNewswire Inc. • 05/06/2026 11:00:00 AM
- Form 3 - Initial statement of beneficial ownership of securities • Edgar (US Regulatory) • 05/01/2026 11:18:47 PM
- Anavex Life Sciences Highlights New Scientific Findings on Shared Biology Between Autism and Alzheimer’s Disease • GlobeNewswire Inc. • 04/14/2026 11:30:00 AM
- Anavex Life Sciences to Present at the 25th Annual Needham Virtual Healthcare Conference • GlobeNewswire Inc. • 04/07/2026 11:30:00 AM
- Anavex withdraws EU approval filing for Alzheimer’s therapy • IH Market News • 03/30/2026 12:39:26 PM
- Anavex Life Sciences Provides Comprehensive Regulatory Update • GlobeNewswire Inc. • 03/30/2026 11:30:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/25/2026 08:06:00 PM
- Anavex withdraws EU marketing application for Alzheimer’s therapy blarcamesine • IH Market News • 03/25/2026 02:06:58 PM
- Anavex Life Sciences Provides Update on Regulatory Review in the EU for Blarcamesine to Treat Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/25/2026 11:30:00 AM
- Anavex Life Sciences Presents New Data from its AD-004 Phase IIb/III Trial at AD/PD 2026 Conference Demonstrating Consistent Correlation Between the Treatment Effect of Oral Blarcamesine and Preservation of Brain Volume in Early Alzheimer’s Disease • GlobeNewswire Inc. • 03/23/2026 11:30:00 AM
- New Scientific Findings Highlight Hypothesis of Autophagy Failure as a Precursor of Amyloid Beta and Tau Pathology in Alzheimer’s Disease • GlobeNewswire Inc. • 03/20/2026 11:30:00 AM
- Anavex Life Sciences Presents Significant Treatment Effects of Blarcamesine in New Advanced Alpha-Synuclein Model of Parkinson’s Disease at AD/PD 2026 Conference • GlobeNewswire Inc. • 03/17/2026 11:30:00 AM
- Anavex Life Sciences to Present at the Citizens Life Sciences Conference • GlobeNewswire Inc. • 03/03/2026 12:30:00 PM
- Anavex Life Sciences to Present at the 46th TD Cowen Annual Health Care Conference • GlobeNewswire Inc. • 02/25/2026 12:30:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 11:07:01 AM
- Anavex Life Sciences Appoints Seasoned Healthcare Leader to Board of Directors • GlobeNewswire Inc. • 02/23/2026 12:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/09/2026 09:40:27 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/09/2026 12:31:17 PM
